Research Capital analyst Andre Uddin raised his target on Knight Therapeutics (Knight Therapeutics Stock Quote, Chart, News, Analysts, Financials TSX:GUD) to C$9.80 from C$8.55, maintaining a “Buy” rating in a May 7 report after what he called another strong quarter. Knight reported Q1 revenue of $148.4-million, up 69% year-over-year and ahead of Uddin’s $110.2-million estimate […]
Leede Financial analyst Douglas Loe raised his target on Eupraxia Pharmaceuticals (Eupraxia Pharmaceuticals Stock Quote, Chart, News, Analysts, Financials NASDAQ:EPRX) to US$15.50 from US$12.75, maintaining a “Buy” rating in a May 5 update after adding esophageal strictures to his valuation model. Loe said the B.C.-based inflammatory disease drug-delivery company presented 36-week data at Digestive Disease […]
Share
Tweet
Share
